IL165007A0 - Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis - Google Patents

Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Info

Publication number: IL165007A0
Authority: IL; Israel
Prior art keywords: methods; apoptosis; polypeptides; nucleic acids; compositions
Prior art date: 2002-05-07

Application number

IL16500704A

Other languages

English (en)

Original Assignee

Senesco Technologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-07

Filing date

2004-11-03

Publication date

2005-12-18

2002-05-07 Priority claimed from US10/141,647 external-priority patent/US7166467B2/en

2004-11-03 Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc

2005-12-18 Publication of IL165007A0 publication Critical patent/IL165007A0/xx

Links

238000000034 method Methods 0.000 title abstract 3
230000006907 apoptotic process Effects 0.000 title abstract 2
108020004707 nucleic acids Proteins 0.000 title abstract 2
102000039446 nucleic acids Human genes 0.000 title abstract 2
150000007523 nucleic acids Chemical class 0.000 title abstract 2
229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
102000048231 Deoxyhypusine synthases Human genes 0.000 abstract 4
108700023218 Deoxyhypusine synthases Proteins 0.000 abstract 4
102000016614 Autophagy-Related Protein 5 Human genes 0.000 abstract 3
108010092776 Autophagy-Related Protein 5 Proteins 0.000 abstract 3
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
108010074105 Factor Va Proteins 0.000 abstract 1
239000000074 antisense oligonucleotide Substances 0.000 abstract 1
238000012230 antisense oligonucleotides Methods 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
230000000977 initiatory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Neurology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Analytical Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Plant Pathology (AREA)
Heart & Thoracic Surgery (AREA)

IL16500704A 2002-05-07 2004-11-03 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis IL165007A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/141,647 US7166467B2 (en)	2001-07-23	2002-05-07	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US10/200,148 US7968523B2 (en)	2001-07-23	2002-07-23	Method for inducing apoptosis using apoptosis-specific EIF5-A
PCT/US2003/014049 WO2003095613A2 (en)	2002-05-07	2003-05-07	Nucleic acids, polypeptides, and methods for modulating apoptosis

Publications (1)

Publication Number	Publication Date
IL165007A0 true IL165007A0 (en)	2005-12-18

Family

ID=29423041

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16500704A IL165007A0 (en)	2002-05-07	2004-11-03	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Country Status (10)

Country	Link
US (3)	US7968523B2 (de)
EP (1)	EP1509251B1 (de)
KR (1)	KR20050007383A (de)
AT (1)	ATE387220T1 (de)
AU (1)	AU2003234482C1 (de)
CA (1)	CA2484144A1 (de)
DE (1)	DE60319369D1 (de)
IL (1)	IL165007A0 (de)
NZ (1)	NZ536958A (de)
WO (1)	WO2003095613A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7166467B2 (en) *	2001-07-23	2007-01-23	Senesco Technologies, Inc.	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7381708B2 (en)	2001-07-23	2008-06-03	Sensco Technologies, Inc.	Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7968523B2 (en) *	2001-07-23	2011-06-28	Senesco Technologies, Inc.	Method for inducing apoptosis using apoptosis-specific EIF5-A
US7595308B2 (en) *	2002-11-18	2009-09-29	Grenpharma Llc	Compositions for treating and/or preventing diseases characterized by the presence of metal ions
WO2004078940A2 (en) *	2003-03-05	2004-09-16	Senesco Technologies, Inc.	USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
NZ544159A (en) *	2003-06-06	2009-04-30	Senesco Technologies Inc	Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
WO2005009445A1 (en) *	2003-07-22	2005-02-03	Cv Therapeutics, Inc.	A1 adenosine receptor antagonists
US20140371299A1 (en) *	2004-06-07	2014-12-18	Senesco Technologies, Inc.	Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
TW200615001A (en) *	2004-07-20	2006-05-16	Senesco Technologies Inc	Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
WO2006047477A1 (en) *	2004-10-22	2006-05-04	Grenpharama Llc	Compositions for treating and/or preventing diseases characterized by the presence of the metal ions
EP1959010A3 (de) *	2004-12-03	2009-02-25	Senesco Technologies, Inc.	Apoptosespezifisches eIF-5A und Polynukleotide zu seiner Kodierung
WO2006060699A2 (en) *	2004-12-03	2006-06-08	Senesco Technologies, Inc.	Methods of increasing seed yield
NZ569075A (en) *	2005-12-13	2011-12-22	Senesco Technologies Inc	Use of elF-5A to kill multiple myeloma cells
NZ596310A (en) *	2006-03-20	2013-05-31	Senesco Technologies Inc	A novel method of protecting islet cells from apoptosis during the donor harvesting process
CN102124108A (zh) *	2007-08-20	2011-07-13	森尼斯科技术公司	Eif-5a1 sirna保护胰岛细胞免受凋亡和维持它们功能性的用途
JP5578522B2 (ja)	2008-05-27	2014-08-27	義規世古	アポトーシス誘導薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5168064A (en)	1990-04-20	1992-12-01	The Regents Of The University Of California	Endo-1,4-β-glucanase gene and its use in plants
US5344846A (en)	1992-12-30	1994-09-06	The United States Of America As Represented By The Department Of Health And Human Services	Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
EP0769552A4 (de) *	1994-06-27	1997-06-18	Toagosei Co Ltd	'antisense'nukleinsäure-zusammensetzung
HUP9801681A3 (en)	1995-02-13	2000-10-30	Novartis Ag	Mutant proteins
US6020139A (en)	1995-04-25	2000-02-01	Oridigm Corporation	S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5849587A (en)	1995-06-09	1998-12-15	Cornell Research Foundation, Inc.	Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6214572B1 (en)	1996-08-09	2001-04-10	The General Hospital Corporation	Programmed cell death and ICH-3
US6124091A (en)	1997-05-30	2000-09-26	Research Corporation Technologies, Inc.	Cell growth-controlling oligonucleotides
EP1002079A2 (de)	1997-06-30	2000-05-24	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Zellwachstumshemmer
US6538182B1 (en)	1999-07-06	2003-03-25	Senesco, Inc.	DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
JP2003510250A (ja)	1999-08-06	2003-03-18	ファルマシア・アンド・アップジョン・カンパニー	スタフィロコッカス・アウレウス延長因子ｐの結晶化および構造決定
ES2182635B1 (es) *	2000-05-25	2004-06-16	Ramon Soler Fornt	Valvula distribuidora de agua para grifos de baño y ducha.
US7968523B2 (en) *	2001-07-23	2011-06-28	Senesco Technologies, Inc.	Method for inducing apoptosis using apoptosis-specific EIF5-A
US7166467B2 (en)	2001-07-23	2007-01-23	Senesco Technologies, Inc.	Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

2002
- 2002-07-23 US US10/200,148 patent/US7968523B2/en not_active Expired - Fee Related
2003
- 2003-05-07 KR KR10-2004-7017741A patent/KR20050007383A/ko not_active Ceased
- 2003-05-07 AT AT03728710T patent/ATE387220T1/de not_active IP Right Cessation
- 2003-05-07 WO PCT/US2003/014049 patent/WO2003095613A2/en not_active Ceased
- 2003-05-07 DE DE60319369T patent/DE60319369D1/de not_active Expired - Lifetime
- 2003-05-07 EP EP03728710A patent/EP1509251B1/de not_active Expired - Lifetime
- 2003-05-07 AU AU2003234482A patent/AU2003234482C1/en not_active Ceased
- 2003-05-07 NZ NZ536958A patent/NZ536958A/en not_active IP Right Cessation
- 2003-05-07 CA CA002484144A patent/CA2484144A1/en not_active Abandoned
2004
- 2004-11-03 IL IL16500704A patent/IL165007A0/xx unknown
2011
- 2011-06-27 US US13/169,667 patent/US20110288156A1/en not_active Abandoned
2013
- 2013-10-11 US US14/051,630 patent/US20140212969A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003234482C1 (en)	2010-02-18
WO2003095613A3 (en)	2004-10-28
ATE387220T1 (de)	2008-03-15
US20030050272A1 (en)	2003-03-13
US7968523B2 (en)	2011-06-28
KR20050007383A (ko)	2005-01-17
NZ536958A (en)	2005-12-23
CA2484144A1 (en)	2003-11-20
DE60319369D1 (de)	2008-04-10
EP1509251B1 (de)	2008-02-27
AU2003234482A1 (en)	2003-11-11
WO2003095613A2 (en)	2003-11-20
EP1509251A2 (de)	2005-03-02
US20140212969A1 (en)	2014-07-31
AU2003234482B2 (en)	2008-07-31
EP1509251A4 (de)	2005-08-10
US20110288156A1 (en)	2011-11-24

Publication	Publication Date	Title
EP1509251A4 (de)	2005-08-10	Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
IL159966A0 (en)	2004-06-20	Nucleic acids, polypeptides, and methods for modulating apoptosis
WO2004035170A3 (en)	2005-08-04	Composition for separating molecules
UA86591C2 (ru)	2009-05-12	Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
DK1675956T3 (da)	2010-11-22	Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
WO2005047511A3 (en)	2005-11-24	Bacterial expression of protease inhibitors and variants thereof
WO2005042029A3 (en)	2005-12-22	Psma formulations and uses thereof
YU84303A (sh)	2006-05-25	Postupak dobijanja cetp inhibitora
PL1682530T3 (pl)	2007-09-28	Podstawione pirolo-indole jako inhibitory PAI-1
WO2005065339A3 (en)	2006-09-21	Cell cycle genes and related methods of using
WO2004007664A3 (en)	2004-07-15	Nucleic acid vectors
YU12903A (sh)	2006-05-25	Derivati aminoalkenilbenzoil-benzofurana ili benzotiopena, postupak za njihovo pripremanje i kompozicije koje ih sadrže
DE602004006871D1 (de)	2007-07-19	Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
DK0724637T3 (da)	1999-06-14	Kortikotropinfrigørende faktor2-receptorer
ATE495255T1 (de)	2011-01-15	Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
WO2003099215A3 (en)	2005-03-31	Antisense modulation of glucocorticoid receptor expression
WO2004113528A3 (en)	2005-10-20	Isoforms of elf-5a: senescence-induced elf5a; wounding-induced elf-5a; growth elf-5a; and dhs
AU7216498A (en)	1998-11-11	Inhibitors of the urokinase receptor
NO20006192L (no)	2001-02-14	Angiostatin-bindingsprotein
WO2003057847A3 (en)	2003-12-11	METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2006060823A3 (en)	2007-02-22	Apoptosis-specific eif-5a and polynucleotides encoding same
AU2003227622A1 (en)	2003-11-10	Methylthiophene carboxanilides
IL173506A0 (en)	2006-07-05	Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (ig-like) domain
TW200634155A (en)	2006-10-01	Polynucleotides of DHS and isoforms of EIF-5A and methods of using same
AU2118500A (en)	2000-08-18	Transcription factor e2f dna-binding domain inhibitor peptides and their use